Short answer
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) filed an 8-K current report with the SEC on June 16, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Dr. Matt Cohen appointed director effective June 12, 2026, adding 25+ years of healthcare investing and portfolio-management experience.
ARROWHEAD PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Dr. Matt Cohen appointed director effective June 12, 2026, adding 25+ years of healthcare investing and portfolio-management experience
- Cohen joined from Vida Ventures after serving as JPMorgan Asset Management’s lead growth-focused healthcare investor since 2005
- $887,000 restricted-stock-unit sign-on grant, vesting over three years, plus standard non-employee director compensation
- Investor relevance: healthcare-investing expertise may strengthen strategic oversight and investor communication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ARROWHEAD PHARMACEUTICALS, INC. 8-K filings
Get the next ARWR 8-K as it lands
Follow ARWR for push alerts, or ask the research agent what this filing means.